Program
WRN Inhibitor AMG 436
Its studies are mostly in Neoplasm Metastasis, led by Amgen.
Furthest: phase 1, since Feb 5, 20261 company-led study, 1 open or runningNext primary completion: Jan 1, 2030 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 11 open or running | phase 1since Feb 5, 2026 | Feb 5, 2026 | Jan 1, 2030phase 1 · NCT07403721 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 5, 2026First study: phase 1 study in Neoplasm MetastasisFirst studyNCT07403721 · 464 planned · United States, Australia, Belgium and more
Ahead
- Jan 1, 2030Primary completion: phase 1 study in Neoplasm MetastasisNCT07403721
TargetBeta
WRN →read by rule
“A selective inhibitor of the Werner syndrome ATP-dependent helicase (WRN), ”NCIt, by rule
Other programs on WRN
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| WRN Inhibitor RO7589831rule | Bayer | phase 2 | 2 |
| WRN Inhibitor GSK4418959rule | GlaxoSmithKline | phase 2 | 1 |
| WRN Inhibitor NDI-219216rule | nimbus-wadjet-inc | phase 2 | 1 |
| WRN Inhibitor EIK1005rule | eikon-therapeutics | phase 2 | 1 |
| WRN Inhibitor MOMA-341rule | moma-therapeutics | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07403721Neoplasm Metastasis · United States, Australia, Belgium and more | 1 | Recruiting | Jan 1, 2030 | 464 |
How it is read
Names in the registry
- “AMG 436”, 1 entry
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.